Literature DB >> 7197539

[Studies on the pharmacology and toxicology of ciclopiroxolamine (author's transl)].

H G Alpermann, E Schütz.   

Abstract

Pharmacological studies with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic, Hoe 296, Batrafen) have been carried out in various test animal species and in isolated organs. The studies did not reveal any indication of effects on the central nervous system or an metabolic functions such as body temperature, urinary and biliary excretion, blood coagulation and acute inflammatory processes. Blood pressure and heart rate were slightly decreased. In the isolated ileum of the guinea pig, slight antagonism towards Ba2+, histamine, carbachol and nicotine was observed. With the doses of ciclopiroxolamine used in local therapy, no systemic pharmacological effects can be expected. Short-term toxicity studies carried out in the usual species of test animals produced oral LD50 values in the range of g/kg of body weight. A 4-week oral administration of 30 mg/kg body weight was virtually symptom-free and the corresponding dose in a 3-month administration was 10 mg/kg. The compound revealed a favourable therapeutic index. As anticipated, the cutaneous tolerance was dependent on animal species, pharmaceutical preparation, concentration of pure drug and duration of the application. The same applies to the tolerance in the vaginal mucosa of the dog. Studies on reproduction toxicology, mutagenicity, carcinogenicity and phototoxicity of ciclopiroxolamine produced no prohibitive findings.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197539

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  11 in total

Review 1.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 2.  Pharmacoeconomic analysis of topical treatments for tinea infections.

Authors:  N H Shear; T R Einarson; S R Arikian; J J Doyle
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

3.  The antitumor activity of the fungicide ciclopirox.

Authors:  Hongyu Zhou; Tao Shen; Yan Luo; Lei Liu; Wenxing Chen; Baoshan Xu; Xiuzhen Han; Jia Pang; Chantal A Rivera; Shile Huang
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

Review 4.  Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.

Authors:  S G Jue; G W Dawson; R N Brogden
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

5.  Ciclopirox olamine induces ferritinophagy and reduces cyst burden in polycystic kidney disease.

Authors:  Priyanka S Radadiya; Mackenzie M Thornton; Rajni V Puri; Sireesha Yerrathota; Johnny Dinh-Phan; Brenda Magenheimer; Dharmalingam Subramaniam; Pamela V Tran; Hao Zhu; Subhashini Bolisetty; James P Calvet; Darren P Wallace; Madhulika Sharma
Journal:  JCI Insight       Date:  2021-03-30

Review 6.  Reposition of the Fungicide Ciclopirox for Cancer Treatment.

Authors:  Zhu Huang; Shile Huang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2021       Impact factor: 3.038

7.  Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A.

Authors:  Tao Shen; Chaowei Shang; Hongyu Zhou; Yan Luo; Mansoureh Barzegar; Yoshinobu Odaka; Yang Wu; Shile Huang
Journal:  Genes Cancer       Date:  2017-03

8.  Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.

Authors:  Chrysovalantou Mihailidou; Pavlos Papakotoulas; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Oncotarget       Date:  2017-12-08

9.  CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective Autophagy in Colorectal Cancer.

Authors:  Jing Zhou; Lu Zhang; Meng Wang; Li Zhou; Xuping Feng; Linli Yu; Jiang Lan; Wei Gao; Chundong Zhang; Youquan Bu; Canhua Huang; Haiyuan Zhang; Yunlong Lei
Journal:  Theranostics       Date:  2019-07-28       Impact factor: 11.556

10.  Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation.

Authors:  Tao Shen; Hongyu Zhou; Chaowei Shang; Yan Luo; Yang Wu; Shile Huang
Journal:  Genes Cancer       Date:  2018-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.